PMID- 34310850
OWN - NLM
STAT- MEDLINE
DCOM- 20211203
LR  - 20211214
IS  - 2050-4527 (Electronic)
IS  - 2050-4527 (Linking)
VI  - 9
IP  - 4
DP  - 2021 Dec
TI  - Antithymocyte globulin is associated with a lower incidence of de novo 
      donor-specific antibody detection in lung transplant recipients: A single-center 
      experience.
PG  - 1418-1427
LID - 10.1002/iid3.491 [doi]
AB  - PURPOSE: Induction immunosuppression has improved the long-term outcomes after 
      lung transplant. This is the first report exploring the association of induction 
      immunosuppression with the development of de novo donor-specific human leukocyte 
      antigen (HLA) antibodies (DSA) in lung transplant recipients (LTR). METHODS: 
      Sixty-seven consecutive primary LTR were followed for 3 years posttransplant. A 
      total of 41/67 (61%) LTR-received induction immunosuppression using a single dose 
      of rabbit Antithymocyte Globulin (rATG; 1.5 mg/kg) within 24 h of transplant. All 
      recipients had a negative flow cytometry crossmatch on the day of transplant. 
      Serum samples at 1, 3, 6, and 12 months posttransplant were assessed for the 
      presence of de novo HLA DSA. RESULTS: De novo HLA DSA were detected in 22/67 
      (32.8%) LTR within 1-year posttransplant. Of these, 9/41 (21.9%) occurred in the 
      induction therapy group and 13/26 (50%) in the noninduction group. Class II DSA 
      were detected in 3/41 (7.3%) LTR who received induction compared to 9/26 (34.6%) 
      LTR without induction immunosuppression (p = .005). Differences in overall 
      survival or freedom from chronic lung allograft dysfunction rates between the two 
      groups were not statistically significant. CONCLUSION: Induction 
      immunosuppression utilizing a modified regimen of single-dose rATG is associated 
      with a significant reduction in de novo DSA production in LTR.
CI  - (c) 2021 The Authors. Immunity, Inflammation and Disease published by John Wiley & 
      Sons Ltd.
FAU - Narula, Tathagat
AU  - Narula T
AD  - Department of Transplantation, Mayo Clinic, Jacksonville, Florida, USA.
FAU - Khouzam, Samir
AU  - Khouzam S
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, 
      Florida, USA.
FAU - Alvarez, Francisco
AU  - Alvarez F
AD  - Department of Transplantation, Mayo Clinic, Jacksonville, Florida, USA.
FAU - Erasmus, David
AU  - Erasmus D
AUID- ORCID: 0000-0001-8851-7466
AD  - Department of Transplantation, Mayo Clinic, Jacksonville, Florida, USA.
FAU - Li, Zhuo
AU  - Li Z
AD  - Health Sciences Research, Mayo Clinic, Jacksonville, Florida, USA.
FAU - Abdelmoneim, Yousif
AU  - Abdelmoneim Y
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, 
      Florida, USA.
FAU - Elrefaei, Mohamed
AU  - Elrefaei M
AUID- ORCID: 0000-0002-2030-4779
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, 
      Florida, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210726
PL  - England
TA  - Immun Inflamm Dis
JT  - Immunity, inflammation and disease
JID - 101635460
RN  - 0 (Antilymphocyte Serum)
SB  - IM
MH  - *Antilymphocyte Serum
MH  - Graft Rejection/epidemiology/prevention & control
MH  - Graft Survival
MH  - Humans
MH  - Incidence
MH  - *Kidney Transplantation
MH  - Lung
MH  - Transplant Recipients
PMC - PMC8589359
COIS- The authors declare that there are no conflict of interests.
EDAT- 2021/07/27 06:00
MHDA- 2021/12/15 06:00
PMCR- 2021/07/26
CRDT- 2021/07/26 17:39
PHST- 2021/05/14 00:00 [received]
PHST- 2021/07/09 00:00 [accepted]
PHST- 2021/07/27 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/07/26 17:39 [entrez]
PHST- 2021/07/26 00:00 [pmc-release]
AID - IID3491 [pii]
AID - 10.1002/iid3.491 [doi]
PST - ppublish
SO  - Immun Inflamm Dis. 2021 Dec;9(4):1418-1427. doi: 10.1002/iid3.491. Epub 2021 Jul 
      26.